Sino Biopharmaceutical Limited
1177
Rangering i aksjer
#1763
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Aksjekurs
$0.68180748
Markedsverdi
$12.14B
Endring (1 dag)
-1.30%
Endring (1 år)
-28.39%
Land
HK
Handel Sino Biopharmaceutical Limited (1177)
Kategori
Healthcare
P/E-forhold for Sino Biopharmaceutical Limited (1177)
P/E-forhold per October 2026 TTM: 33.58
Ifølge Sino Biopharmaceutical Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 33.58. Ved slutten av 2023 hadde selskapet en P/E på 30.45.
P/E-forholdshistorikk for Sino Biopharmaceutical Limited fra 2000 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 33.58 | 125.39% |
| 2024 | 14.90 | -51.06% |
| 2023 | 30.45 | 3.06% |
| 2022 | 29.54 | 417.13% |
| 2021 | 5.71 | -86.65% |
| 2020 | 42.81 | 64.50% |
| 2019 | 26.02 | 320.41% |
| 2018 | 6.19 | -84.21% |
| 2017 | 39.19 | 85.12% |
| 2016 | 21.17 | -28.05% |
| 2015 | 29.42 | 27.86% |
| 2014 | 23.01 | -21.27% |
| 2013 | 29.23 | 42.22% |
| 2012 | 20.55 | -16.96% |
| 2011 | 24.75 | 0.93% |
| 2010 | 24.52 | -12.56% |
| 2009 | 28.05 | 251.36% |
| 2008 | 7.98 | -46.51% |
| 2007 | 14.92 | -0.88% |
| 2006 | 15.06 | 609.85% |
| 2005 | 2.12 | -82.99% |
| 2004 | 12.47 | -8.04% |
| 2003 | 13.56 | 192.22% |
| 2002 | 4.64 | 9.00% |
| 2001 | 4.26 | -13.69% |
| 2000 | 4.93 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 24.47 | -27.13% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| 223.52 | 565.57% |
US
|
|
| - | - |
IT
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.